Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

BACKGROUND: Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Head Neck
Hauptverfasser: Andtbacka, Robert H. I., Agarwala, Sanjiv S., Ollila, David W., Hallmeyer, Sigrun, Milhem, Mohammed, Amatruda, Thomas, Nemunaitis, John J., Harrington, Kevin J., Chen, Lisa, Shilkrut, Mark, Ross, Merrick, Kaufman, Howard L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2016
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5129499/
https://ncbi.nlm.nih.gov/pubmed/27407058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.24522
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge